Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

The Lancet

Volumn 389, Issue 10086, 2017, Pages 2287-2303

  Blauvelt, Andrew ^a   de Bruin Weller, Marjolein ^b   Gooderham, Melinda ^c   Cather, Jennifer C ^d   Weisman, Jamie ^e   Pariser, David ^f   Simpson, Eric L ^g   Papp, Kim A ^h   Hong, H Chih Ho ⁱ   Rubel, Diana ^j   Foley, Peter ^k   Prens, Errol ^l   Griffiths, Christopher E M ^m   Etoh, Takafumi ⁿ   Pinto, Pedro Herranz ^o   Pujol, Ramon M ^p   Szepietowski, Jacek C ^q   Ettler, Karel ^r   Kemény, Lajos ^s   Zhu, Xiaoping ^t   Akinlade, Bolanle ^u   Hultsch, Thomas ^v   Mastey, Vera ^u   Gadkari, Abhijit ^u   Eckert, Laurent ^w   Amin, Nikhil ^u   Graham, Neil M H ^u   Pirozzi, Gianluca ^w   Stahl, Neil ^u   Yancopoulos, George D ^u   Shumel, Brad ^u   more..

^a OREGON MEDICAL RESEARCH CENTER   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c QUEEN S UNIVERSITY   (Canada)

^d Modern Dermatology Aesthetics Center   (United States)

^e Advanced Clinical Research   (United States)

^f EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h K Papp Clinical Research and Probity Medical Research   (Canada)

ⁱ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^j AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^k UNIVERSITY OF MELBOURNE   (Australia)

^l ERASMUS MEDICAL CENTER   (Netherlands)

^m UNIVERSITY OF MANCHESTER   (United Kingdom)

ⁿ Department on Pediatrics   (Japan)

^o HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^p HOSPITAL DEL MAR   (Spain)

^q Regeneron Pharmaceuticals Inc ^*  (Poland)

^r Dermatology and Venereology   (Czech Republic)

^s UNIVERSITY OF SZEGED   (Hungary)

^t REGENERON PHARMACEUTICALS INC   (United States)

^u REGENERON PHARMACEUTICALS INC   (United States)

^v SANOFI   (United States)

^w SANOFI   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DUPILUMAB; PLACEBO; ANTIASTHMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; ASTHMA; ATOPIC DERMATITIS; CONJUNCTIVITIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FEMALE; HEADACHE; HERPES SIMPLEX; HERPES VIRUS INFECTION; HERPES ZOSTER; HERPES ZOSTER OPHTHALMICUS; HUMAN; INFLUENZA; INJECTION SITE REACTION; LOADING DRUG DOSE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DERMATITIS, ATOPIC; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; UNITED STATES;

ADRENAL CORTEX HORMONES; ADULT; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; DERMATITIS, ATOPIC; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES;

EID: 85018795523     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)31191-1     Document Type: Article

References (41)

1. Weidinger, S, Novak, N, Atopic dermatitis. Lancet 387 (2016), 1109–1122.
2. Hanifin, JM, Rajka, G, Diagnostic features of atopic dermatitis. Acta Dermatovener (Stockholm) 60 (1980), 44–47.
3. Eichenfield, LF, Tom, WL, Chamlin, SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol 70 (2014), 338–351.
4. Silverberg, JI, Hanifin, JM, Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol 132 (2013), 1132–1138.
5. Silverberg, JI, Nelson, DB, Yosipovitch, G, Addressing treatment challenges in atopic dermatitis with novel topical therapies. J Dermatolog Treat 27 (2016), 568–576.
6. Berth-Jones, J, Graham-Brown, RA, Marks, R, et al. Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis. Br J Dermatol 136 (1997), 76–81.
7. Zonneveld, IM, De Rie, MA, Beljaards, RC, et al. The long-term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: a comparison of two dosage regimens. Br J Dermatol 135 (1996), 15–20.
8. Kim, JE, Shin, JM, Ko, JY, Ro, YS, Importance of concomitant topical therapy in moderate-to-severe atopic dermatitis treated with cyclosporine. Dermatol Ther 29 (2016), 120–125.
9. van der Schaft, J, Politiek, K, van den Reek, JM, et al. Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis. Br J Dermatol 172 (2015), 1621–1627.
10. van der Schaft, J, Politiek, K, van den Reek, JM, et al. Drug survival for azathioprine and enteric-coated mycophenolate sodium in a long-term daily practice cohort of adult patients with atopic dermatitis. Br J Dermatol 175 (2016), 199–202.
11. Haeck, IM, Knol, MJ, Ten Berge, O, van Velsen, SG, de Bruin-Weller, MS, Bruijnzeel-Koomen, CA, Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol 64 (2011), 1074–1084.
12. Granlund, H, Erkko, P, Remitz, A, et al. Comparison of cyclosporin and UVAB phototherapy for intermittent one-year treatment of atopic dermatitis. Acta Derm Venereol 81 (2001), 22–27.
13. Politiek, K, van der Schaft, J, Coenraads, PJ, de Bruin-Weller, MS, Schuttelaar, ML, Drug survival for methotrexate in a daily practice cohort of adult patients with severe atopic dermatitis. Br J Dermatol 174 (2016), 201–203.
14. Ring, J, Alomar, A, Bieber, T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 26 (2012), 1045–1060.
15. Ring, J, Alomar, A, Bieber, T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part II. J Eur Acad Dermatol Venereol 26 (2012), 1176–1193.
16. Sidbury, R, Davis, DM, Cohen, DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol 71 (2014), 327–349.
17. Sidbury, R, Davis, DM, Cohen, DE, et al. Guidelines of care for the management of atopic dermatitis: section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol 71 (2014), 1218–1233.
18. Eichenfield, LF, Tom, WL, Berger, TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 71 (2014), 116–132.
19. Katayama, I, et al. Japanese guidelines for atopic dermatitis 2016. Allergol Int, 2016 http://dx.doi.org/10.1016/j.alit.2016.12.003.
20. Garritsen, FM, Brouwer, MW, Limpens, J, Spuls, PI, Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research. Br J Dermatol 170 (2014), 501–513.
21. Gandhi, NA, Bennett, BL, Graham, NMH, Pirozzi, G, Stahl, N, Yancopoulos, GD, Targeting key proximal drivers in type 2 inflammation in disease. Nature Rev Drug Disc 15 (2015), 35–50.
22. Wenzel, S, Castro, M, Corren, J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta-agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging study. Lancet 388 (2016), 31–44.
23. Bachert, C, Mannent, L, Naclerio, RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomised clinical trial. JAMA 315 (2016), 469–479.
24. Beck, LA, Thaçi, D, Hamilton, JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371 (2014), 130–139.
25. Thaçi, D, Simpson, EL, Beck, LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 387 (2016), 40–52.
26. Simpson, EL, Gadkari, A, Worm, M, et al. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomised, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). J Am Acad Dermatol 75 (2016), 506–515.
27. Simpson, EL, Bieber, T, Guttman-Yassky, E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 375 (2016), 2335–2348.
28. Jacob, SE, Steele, T, Corticosteroid classes: a quick reference guide including patch test substances and cross-reactivity. J Amer Acad Dermatol 54 (2006), 723–727.
29. Simpson E, Beck L, Gadkari A, et al. Defining a responder on the peak pruritus numerical rating scale (NRS) in patients with moderate-to-severe atopic dermatitis: detailed analysis from randomized trials of dupilumab. American Academy of Dermatology, 75th Annual Meeting, March 3–7, 2017; Orlando, FL, USA: Abstr 4789.
30. Schram, ME, Spuls, PI, Leeflang, MM, Lindeboom, R, Bos, JD, Schmitt, J, EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy 67 (2012), 99–106.
31. Basra, MK, Salek, MS, Camilleri, L, Sturkey, R, Finlay, AY, Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology 230 (2015), 27–33.
32. Bjelland, I, Dahl, AA, Haug, TT, Neckelmann, D, The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 52 (2002), 69–77.
33. Simpson, EL, Bieber, T, Eckert, L, et al. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol 74 (2016), 491–498.
34. Sanchez-Perez, J, Dauden-Telo, E, Mora, AM, Lara Sruinyac, N, Impact of atopic dermatitis on health-related quality of life in Spanish children and adults: the PSEDA study. Actas Dermosifiliogr 104 (2013), 44–52.
35. Von Kobyletzki, LB, Thomas, KS, Schmitt, J, et al. What factors are important to patients when assessing treatment response: an international cross-sectional survey. Acta Derm Venereol 96 (2017), 86–90.
36. Silverberg, JI, Garg, NK, Paller, AS, Fishbein, AB, Zee, PC, Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. J Invest Dermatol 135 (2015), 56–66.
37. Yaghmaie, P, Koudelka, CW, Simpson, EL, Mental health comorbidity in atopic dermatitis. J Allergy Clin Immunol 131 (2013), 428–433.
38. Wenzel, S, Ford, L, Pearlman, D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 368 (2013), 2455–2466.
39. Velsen van, SGA, Haeck, IM, Bruijnzeel-Koomen, AFM, Percutaneous absorption of potent topical corticosteroids in patients with severe atopic dermatitis. J Am Acad Dermatol 63 (2010), 911–913.
40. Decani, S, Federighi, V, Baruzzi, E, Sardella, A, Lodi, G, Iatrogenic Cushing's syndrome and topical steroid therapy: case series and review of the literature. J Dermatol Treatment 25 (2014), 495–500.
41. Bieber, T, Straeter, B, Off-label prescriptions for atopic dermatitis in Europe. Allergy 70 (2015), 6–11.